Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers

Official Title

A Phase I/II Study of IMCnyeso, HLA- A*0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A*0201 Positive Patients With Advanced NY-ESO-1 and/or LAGE - 1A Positive Cancer

Summary:

IMCnyeso is a new biological therapy designed for the treatment of cancers which express NY-ESO-1 and/or LAGE-1A. This is a first-in-human trial designed to evaluate the safety and efficacy of IMCnyeso in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for NY-ESO-1 and/or LAGE-A1.

Trial Description

Primary Outcome:

  • Phase I: Incidence of dose-limiting toxicities (DLT)
  • Phase I: incidence and severity of adverse events (AE)
  • Phase I: changes in laboratory parameters
  • Phase I: changes in body temperature
  • Phase I: changes in pulse
  • Phase I: changes in respiratory rate
  • Phase I: changes in blood pressure
  • Phase I: changes in electrocardiogram parameters
  • Phase I: dose interruptions, reductions, and discontinuations
  • Phase II: Best overall response (BOR)
Secondary Outcome:
  • Phase II: incidence and severity of adverse events (AE)
  • Phase II: changes in laboratory parameters
  • Phase II: changes in body temperature
  • Phase II: changes in pulse
  • Phase II: changes in respiratory rate
  • Phase II: changes in blood pressure
  • Phase II: changes in electrocardiogram parameters
  • Phase II: dose interruptions, reductions, and discontinuations
  • Phase I: Best overall response (BOR)
  • Progression-free survival
  • Duration of response
  • Overall survival
  • Pharmacokinetics Area under the plasma concentration-time curve (AUC)
  • Pharmacokinetics The maximum observed plasma drug concentration after single dose administration (Cmax)
  • Pharmacokinetics The time to reach maximum plasma concentration (Tmax)
  • Pharmacokinetics The elimination half-life (t1/2)
  • Immunogenicity the incidence of anti-IMCnyeso antibody formation Immunogenicity the incidence of anti-IMCnyeso antibody formation
This is a multi-centre, open label, dose finding Phase 1/2 study of single agent IMCnyeso administered in patients with NY-ESO-1 and/or LAGE-A1 positive tumours. The primary objective of the dose escalation phase (Arm 1) is to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) of IMCnyeso in patients with advanced solid tumours. Preliminary efficacy will be evaluated in Arm 2.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society